Browsing Tag
Memorial Sloan Kettering Cancer Center
10 posts
AstraZeneca, Daiichi Sankyo secure FDA approval for Enhertu in two early breast cancer indications
Enhertu is moving from late-stage control to early-stage cure. AstraZeneca and Daiichi Sankyo now face the bigger test: adoption.
How FMISO PET imaging could reduce toxicity in oropharyngeal carcinoma
Can FMISO PET imaging reduce radiation toxicity in cancer care? Discover how Juniper Biosciences is reshaping treatment strategies.
Lilly bets up to $2.3bn on Ajax Therapeutics to crack the resistant myelofibrosis market with a Type II JAK2 inhibitor
Lilly is paying up to $2.3B for Ajax Therapeutics' Type II JAK2 inhibitor. The real question is whether it can crack Incyte's Jakafi grip on myelofibrosis.
AACR Annual Meeting 2026: what cancer researchers and pharma professionals need to know before San Diego
AACR Annual Meeting 2026 runs April 17-22 at San Diego Convention Center. Over 7,400 abstracts, six plenaries, AI, CAR T, ADCs and RAS inhibitor data.
Why did Sellas Life Sciences file to register 19.69m shares, and how could this affect SLS stock performance in 2025?
Sellas registers 19.69 M shares for resale after a warrant deal. Discover what it means for dilution, stock sentiment, and upcoming biotech catalysts.
Precision Cell Systems consolidates cell analysis tech through dual acquisitions to serve 700+ research customers
Discover how Precision Cell Systems is consolidating cell analysis tech through key acquisitions to serve 700+ research customers globally.
Y-mAbs Therapeutics showcases promising CD38-SADA translational pharmacokinetics data at AACR 2025
Find out how Y-mAbs’ CD38-SADA translational pharmacokinetics study at AACR 2025 is advancing next-gen cancer therapies with promising clinical insights.
Memorial Sloan Kettering Cancer Center partners with AWS to advance AI-driven cancer research
Memorial Sloan Kettering Cancer Center has joined forces with Amazon Web Services, an Amazon.com, Inc. company, to leverage…
Lilly bags Retevmo FDA approval for RET-driven lung and thyroid cancers
Retevmo FDA approval : Eli Lilly and Company (Lilly) has secured approval from the US Food and Drug…
Y-mAbs begins roll-out of BLA of naxitamab to FDA for neuroblastoma
US biopharma company Y-mAbs Therapeutics has submitted the first portions of its biologics license application (BLA) for naxitamab…